Skip to main content

Table 1 Recent clinical trials concerning immune-checkpoint inhibitors in pancreatic cancer

From: Tumor microenvironment participates in metastasis of pancreatic cancer

NCT Number

Status

Phase

Tumor types

Interventions

Monotherapy/Combination

NCT02305186

Recruiting

Phase 1/2

Pancreatic Cancer

Pembrolizumab + Neoadjuvant chemoradiation

Combination

NCT02930902

Recruiting

Phase 1

Pancreatic Cancer

Pembrolizumab + Paricalcitol + Surgical Resection or Pembrolizumab + Paricalcitol + Surgical Resection + Gemcitabine + Nab-pacilitaxel

Combination

NCT02451982

Recruiting

Phase 1/2

Pancreatic Cancer

Cyclophosphamide + GVAX pancreatic cancer or Cyclophosphamide + GVAX pancreatic cancer + Nivolumab

Combination

NCT02866383

Recruiting

Phase 2

Metastatic Pancreatic Cancer

Nivolumab + Ipilimumab + Radiotherapy

Combination

NCT03519308

Recruiting

Early Phase 1

Pancreatic Cancer

Nivolumab + Nab-Paclitaxel + Gemcitabine + Paricalcitol

Combination

NCT03404960

Recruiting

Phase 1/2

Pancreatic Cancer

Niraparib + Nivolumab or Niraparib + Ipilimumab

Combination

NCT03104439

Recruiting

Phase 2

Microsatellite Stable Colorectal Cancer

Pancreatic Cancer

MSI High Colorectal Cancer

Nivolumab + Ipilimumab + Radiation therapy

Combination

NCT01473940

Active, not recruiting

Phase 1

Ductal Cell Adenocarcinoma of the Pancreas

Recurrent Pancreatic Cancer

Stage III Pancreatic Cancer

Stage IV Pancreatic Cancer

Ipilimuma + Gemcitabine hydrochloride

Combination

NCT01896869

Suspended

Phase 2

Metastatic Pancreatic Adenocarcinoma

Ipilimumab + Vaccine + FOLFIRINOX

Combination